RecruitingNot ApplicableNCT05495087

IHT for Mild Cognitive Impairment

Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment


Sponsor

University of North Texas Health Science Center

Enrollment

66 participants

Start Date

Feb 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).


Eligibility

Min Age: 55 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called IHT Treatment and Sham-IHT Control for people with memory impairment and mild cognitive impairment. The study is currently recruiting participants at 1 location. People eligible for this study include aged 55 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEIHT Treatment

IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.

OTHERSham-IHT Control

Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.


Locations(1)

University of North Texas Health Science Center

Fort Worth, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05495087


Related Trials